- Home
- ANGO vs RCS Comparison
ANGO vs RCS Comparison
Compare ANGO & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- RCS
- Stock Information
- Founded
- ANGO 1988
- RCS 1994
- Country
- ANGO United States
- RCS United States
- Employees
- ANGO N/A
- RCS N/A
- Industry
- ANGO Medical/Dental Instruments
- RCS Investment Managers
- Sector
- ANGO Health Care
- RCS Finance
- Exchange
- ANGO Nasdaq
- RCS Nasdaq
- Market Cap
- ANGO 279.1M
- RCS 292.8M
- IPO Year
- ANGO 2004
- RCS N/A
- Fundamental
- Price
- ANGO $9.78
- RCS $6.37
- Analyst Decision
- ANGO Strong Buy
- RCS
- Analyst Count
- ANGO 3
- RCS 0
- Target Price
- ANGO $13.00
- RCS N/A
- AVG Volume (30 Days)
- ANGO 511.4K
- RCS 141.1K
- Earning Date
- ANGO 04-02-2025
- RCS 01-01-0001
- Dividend Yield
- ANGO N/A
- RCS 10.12%
- EPS Growth
- ANGO N/A
- RCS N/A
- EPS
- ANGO N/A
- RCS N/A
- Revenue
- ANGO $286,498,000.00
- RCS N/A
- Revenue This Year
- ANGO N/A
- RCS N/A
- Revenue Next Year
- ANGO $6.63
- RCS N/A
- P/E Ratio
- ANGO N/A
- RCS N/A
- Revenue Growth
- ANGO N/A
- RCS N/A
- 52 Week Low
- ANGO $5.26
- RCS $4.51
- 52 Week High
- ANGO $13.50
- RCS $6.31
- Technical
- Relative Strength Index (RSI)
- ANGO 48.76
- RCS 47.88
- Support Level
- ANGO $8.95
- RCS $6.22
- Resistance Level
- ANGO $9.84
- RCS $6.32
- Average True Range (ATR)
- ANGO 0.47
- RCS 0.13
- MACD
- ANGO 0.09
- RCS 0.01
- Stochastic Oscillator
- ANGO 85.99
- RCS 45.83
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with this objective.